Going Beyond “Bio-markers,” Think “Life-markers”

Laren Tan; Geoff Chupp; Mario Castro; Monica Kraft

doi:10.1016/j.chest.2019.08.2210

Going Beyond “Bio-markers,” Think “Life-markers”

Laren Tan
, Geoff Chupp
, Mario Castro
, Monica Kraft

Pulmonary, Critical Care, Hyperbaric, Allergy and Sleep Medicine Division

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Pages (from-to)	503-505
Number of pages	3
Journal	Chest
Volume	157
Issue number	3
DOIs	https://doi.org/10.1016/j.chest.2019.08.2210
State	Published - Mar 2020

ASJC Scopus Subject Areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.chest.2019.08.2210

OpenUrl availability

Full text

Cite this

@article{80d01bab93da4277a052e9a5e02925fb,

title = "Going Beyond “Bio-markers,” Think “Life-markers”",

author = "Laren Tan and Geoff Chupp and Mario Castro and Monica Kraft",

note = "Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: L. T. has been a member of the advisory boards for AstraZeneca, Sanofi, Regeneron, and Boehringer Ingelheim; a consultant for Boston Scientific; and a member of the Speakers Bureau for Sanofi, Regeneron, Boehringer Ingelheim, and AstraZeneca. G. C. has been a member of the advisory boards for Genentech, AstraZeneca, Regeneron, Boehringer Ingelheim, GlaxoSmithKline, and Teva; a member of the Speakers Bureau for AstraZeneca, Regeneron, Genentech, Boehringer Ingelheim, GlaxoSmithKline, and Circassia; and a Clinical Trial Principal Investigator for AstraZeneca, Genentech, GlaxoSmithKline, and Holaira. M. C. has been a member of the advisory board for Novartis; a consultant for Sanofi, Genentech, Theravance, VIDA, and TEVA; a member of the Speakers Bureau for AstraZeneca, GlaxoSmithKline, Sanofi, Genentech, and TEVA; has received research funding from the National Institutes of Health, American Lung Association, the Patient-Centered Outcomes Research Institute, AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, and Sanofi; and has received royalties from Elsevier. M. K. has received research funding (funds paid to University of Arizona) from the National Institutes of Health, Sanofi, Regeneron, and Chiesi; has served as a consultant for AstraZeneca and Sanofi; and has received royalties from Elsevier. Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: L. T. has been a member of the advisory boards for AstraZeneca, Sanofi, Regeneron, and Boehringer Ingelheim; a consultant for Boston Scientific; and a member of the Speakers Bureau for Sanofi, Regeneron, Boehringer Ingelheim, and AstraZeneca. G. C. has been a member of the advisory boards for Genentech, AstraZeneca, Regeneron, Boehringer Ingelheim, GlaxoSmithKline, and Teva; a member of the Speakers Bureau for AstraZeneca, Regeneron, Genentech, Boehringer Ingelheim, GlaxoSmithKline, and Circassia; and a Clinical Trial Principal Investigator for AstraZeneca, Genentech, GlaxoSmithKline, and Holaira. M. C. has been a member of the advisory board for Novartis; a consultant for Sanofi, Genentech, Theravance, VIDA, and TEVA; a member of the Speakers Bureau for AstraZeneca, GlaxoSmithKline, Sanofi, Genentech, and TEVA; has received research funding from the National Institutes of Health , American Lung Association , the Patient-Centered Outcomes Research Institute , AstraZeneca , Chiesi , GlaxoSmithKline , Novartis , and Sanofi ; and has received royalties from Elsevier. M. K. has received research funding (funds paid to University of Arizona ) from the National Institutes of Health , Sanofi , Regeneron , and Chiesi ; has served as a consultant for AstraZeneca and Sanofi; and has received royalties from Elsevier. ",

year = "2020",

month = mar,

doi = "10.1016/j.chest.2019.08.2210",

language = "English",

volume = "157",

pages = "503--505",

journal = "Chest",

issn = "0012-3692",

number = "3",

}

TY - JOUR

T1 - Going Beyond “Bio-markers,” Think “Life-markers”

AU - Tan, Laren

AU - Chupp, Geoff

AU - Castro, Mario

AU - Kraft, Monica

N1 - Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: L. T. has been a member of the advisory boards for AstraZeneca, Sanofi, Regeneron, and Boehringer Ingelheim; a consultant for Boston Scientific; and a member of the Speakers Bureau for Sanofi, Regeneron, Boehringer Ingelheim, and AstraZeneca. G. C. has been a member of the advisory boards for Genentech, AstraZeneca, Regeneron, Boehringer Ingelheim, GlaxoSmithKline, and Teva; a member of the Speakers Bureau for AstraZeneca, Regeneron, Genentech, Boehringer Ingelheim, GlaxoSmithKline, and Circassia; and a Clinical Trial Principal Investigator for AstraZeneca, Genentech, GlaxoSmithKline, and Holaira. M. C. has been a member of the advisory board for Novartis; a consultant for Sanofi, Genentech, Theravance, VIDA, and TEVA; a member of the Speakers Bureau for AstraZeneca, GlaxoSmithKline, Sanofi, Genentech, and TEVA; has received research funding from the National Institutes of Health, American Lung Association, the Patient-Centered Outcomes Research Institute, AstraZeneca, Chiesi, GlaxoSmithKline, Novartis, and Sanofi; and has received royalties from Elsevier. M. K. has received research funding (funds paid to University of Arizona) from the National Institutes of Health, Sanofi, Regeneron, and Chiesi; has served as a consultant for AstraZeneca and Sanofi; and has received royalties from Elsevier. Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: L. T. has been a member of the advisory boards for AstraZeneca, Sanofi, Regeneron, and Boehringer Ingelheim; a consultant for Boston Scientific; and a member of the Speakers Bureau for Sanofi, Regeneron, Boehringer Ingelheim, and AstraZeneca. G. C. has been a member of the advisory boards for Genentech, AstraZeneca, Regeneron, Boehringer Ingelheim, GlaxoSmithKline, and Teva; a member of the Speakers Bureau for AstraZeneca, Regeneron, Genentech, Boehringer Ingelheim, GlaxoSmithKline, and Circassia; and a Clinical Trial Principal Investigator for AstraZeneca, Genentech, GlaxoSmithKline, and Holaira. M. C. has been a member of the advisory board for Novartis; a consultant for Sanofi, Genentech, Theravance, VIDA, and TEVA; a member of the Speakers Bureau for AstraZeneca, GlaxoSmithKline, Sanofi, Genentech, and TEVA; has received research funding from the National Institutes of Health , American Lung Association , the Patient-Centered Outcomes Research Institute , AstraZeneca , Chiesi , GlaxoSmithKline , Novartis , and Sanofi ; and has received royalties from Elsevier. M. K. has received research funding (funds paid to University of Arizona ) from the National Institutes of Health , Sanofi , Regeneron , and Chiesi ; has served as a consultant for AstraZeneca and Sanofi; and has received royalties from Elsevier.

PY - 2020/3

Y1 - 2020/3

UR - https://www.scopus.com/pages/publications/85079607748

UR - https://www.scopus.com/pages/publications/85079607748#tab=citedBy

UR - https://www.mendeley.com/catalogue/08762d2a-2c41-33b0-bb34-b8fd62dcecca/

U2 - 10.1016/j.chest.2019.08.2210

DO - 10.1016/j.chest.2019.08.2210

M3 - Editorial

SN - 0012-3692

VL - 157

SP - 503

EP - 505

JO - Chest

JF - Chest

IS - 3

ER -

Going Beyond “Bio-markers,” Think “Life-markers”

ASJC Scopus Subject Areas

Access to Document

OpenUrl availability

Other files and links

Cite this